US20130195808A1 - Mesenchymal stem cell and a method of use thereof - Google Patents
Mesenchymal stem cell and a method of use thereof Download PDFInfo
- Publication number
- US20130195808A1 US20130195808A1 US13/733,008 US201313733008A US2013195808A1 US 20130195808 A1 US20130195808 A1 US 20130195808A1 US 201313733008 A US201313733008 A US 201313733008A US 2013195808 A1 US2013195808 A1 US 2013195808A1
- Authority
- US
- United States
- Prior art keywords
- cells
- neurodegeneration
- cell population
- bone marrow
- treating
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0676—Pancreatic cells
-
- C12N5/0675—
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/51—Umbilical cord; Umbilical cord blood; Umbilical stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0618—Cells of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0618—Cells of the nervous system
- C12N5/0622—Glial cells, e.g. astrocytes, oligodendrocytes; Schwann cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0664—Dental pulp stem cells, Dental follicle stem cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0665—Blood-borne mesenchymal stem cells, e.g. from umbilical cord blood
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0666—Mesenchymal stem cells from hair follicles
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0667—Adipose-derived stem cells [ADSC]; Adipose stromal stem cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0668—Mesenchymal stem cells from other natural sources
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/13—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells
- C12N2506/1346—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from mesenchymal stem cells
- C12N2506/1353—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from mesenchymal stem cells from bone marrow mesenchymal stem cells (BM-MSC)
Definitions
- the present invention relates to cells derived from bone marrow cells, cord blood cells, or embryonic hepatic tissues that can differentiate into neural cells, and cell fractions containing such cells. It is expected that these cells and cell fractions can be used to treat neurological diseases, particularly in autologous transplantation therapy.
- oligodendrocytes i.e., oligodendroglia
- oligodendroglia i.e., oligodendroglia
- Basal D. R. et al., 1994. Exp. Neurol. 125:268-77; Blakemore W. F., Crang A. J., 1988.
- myelin-forming cells such as Schwann cells (Blakemore W. F., 1977. Nature 266:68-9; Blakemore W. F., Crang A. J., 1988. Dev. Neurosci. 10:1-11; Honmou O. et al., 1996. J.
- Neural progenitor cells or stem cells derived from brain have the ability to self-renewal and differentiate into various lineages of neurons and glia cells (Gage F. H. et al., 1995. Proc. Natl. Acad. Sci. USA. 92:11879-83; Lois C., Alvarez-Buylla A., 1993. Proc. Natl. Acad. Sci. USA. 90:2074-7; Morshead C. M. et al., 1994. Neuron 13:1071-82; Reynolds B. A., Weiss S., 1992. Science 255:1707-10).
- neural stem cells were revealed to be able to differentiate or transform into hematopoietic cells in vivo, suggesting that neural progenitor (stem) cells are not restricted to the neural cell lineage (Bjornson C. R. et al., 1999. Science 283:534-7).
- bone marrow stromal cells (not mesenchymal stem cells in the bone marrow) are reported to differentiate into astrocytes by the injection into the lateral ventricles of neonatal mice (Kopen G. C. et al., Proc. Natl. Acad. Sci. USA. 96:10711-6), and into neurons in vitro when cultured under appropriate cell culture conditions (Woodbury D. et al., 2000. J. Neurosci. Res. 61:364-70).
- the present inventors have previously isolated and cultured neural stem cells from adult human brain, and established some cell lines. By studying their functions, the inventors newly discovered that the neural stem cells have pluripotency and the ability to self-renewal. Specifically, single-cell expansion of neural progenitor (stem) cells obtained from adult human brain was conducted to establish cell lines; the established cells were then subjected to in vitro clonal analysis. The result showed that the cell lines had pluripotency (namely, differentiation into neuron, astroglia (or astrocyte), and oligodendroglia (i.e., oligodendrocyte)) and the ability to self-renewal (namely, proliferation potency). Thus, these cells were confirmed to possess the characteristics of neural stem cell.
- pluripotency namely, differentiation into neuron, astroglia (or astrocyte), and oligodendroglia (i.e., oligodendrocyte)
- proliferation potency namely, proliferation potency
- Transplantation of these cells indeed resulted in very favorable graft survival, migration, and differentiation in cerebral ischemic model rats or injury model rats. Furthermore, transplantation of the cells was found to result in functional myelin sheath formation in spinal cord demyelination model rats. Thus, such transplantation allows remyelination of the demyelinated axon and restoration of the neural function in the rat spinal cord demyelination model. Effectiveness of such transplantation therapy using these cells was confirmed by histological, electrophysiological, and behavior studies.
- transplantation of cultured neural stem cells which have been isolated from a small amount of neural tissue collected from the cerebrum of a patient, into the lesion of the brain or the spinal cord of the patient seems to be a widely applicable in autotransplantation therapy.
- an objective of the present invention is to provide cellular material that is useful in the treatment of neurological diseases, and which can be prepared safely and readily.
- Another objective of the present invention is to provide a method for treating neurological diseases, preferably a method for autotransplantation therapy, using the cellular material.
- the present inventors focused on the technique of collecting bone marrow cells from bone marrow, a simpler technique as compared to the collection of neural stem cells and routinely used in today's medical practice.
- they collected bone marrow cells from mouse bone marrow, isolated mononuclear cell fraction, and then transplanted this fraction as donor cells into spinal cord demyelination model rats.
- the demyelinated axon gets remyelination by the treatment.
- the present inventors newly revealed that the mononuclear cell fraction prepared from bone marrow cells have the ability to differentiate into neural cells.
- cell fractions containing mesodermal stem cells, mesenchymal stem cell, stromal cells, and AC133-positive cells that were isolated from the mononuclear cell fraction had the ability to differentiate into neural cells.
- these cell fractions can also be prepared from cord blood cells.
- AC133-positive cells can be prepared from embryonic hepatic tissues.
- the present invention provides cell fractions containing cells capable of differentiating into neural cells, which are isolated from bone marrow cells, cord blood cells, and embryonic hepatic tissues.
- such cell fractions contain mesenchymal stem cells having the following character: SH2(+), SH3(+), SH4(+), CD29(+), CD44(+), CD14( ⁇ ), CD34( ⁇ ), and CD45( ⁇ ).
- such cell fractions contain stromal cells having the following characteristics: Lin( ⁇ ), Sca-1(+), CD10(+), CD11D(+), CD44(+), CD45(+), CD71(+), CD90(+), CD105(+), CDW123(+), CD127(+), CD164(+), fibronectin (+), ALPH (+), and collagenase-1(+).
- such cell fractions contain cells having the character AC133(+).
- the present invention provides cells capable of differentiating into neural cells, which are contained in the above-mentioned cell fraction.
- the present invention provides compositions for treating neurological disease, which contain the above-mentioned mononuclear cell fractions or the above-mentioned cells.
- the neurological disease is selected from the group consisting of: central and peripheral demyelinating diseases; central and peripheral degenerative diseases; cerebral apoplexy (cerebral infarction, cerebral hemorrhage, subarachnoid hemorrhage); brain tumor; dysfunction of higher function of the brain (the term “higher function of the brain” involves the cognitive function, short and long memory, speech, etc.); psychiatric diseases; dementia; infectious diseases; epilepsy; traumatic neurological diseases; and infarction of spinal cord diseases.
- the present invention provides therapeutic methods for neurological diseases, which comprises transplanting of the above-mentioned mononuclear cell fractions, cells, or compositions.
- the donor cells are derived from a recipient.
- the present invention provides mononuclear cell fractions isolated from bone marrow cells, cord blood cells, or embryonic hepatic tissues, wherein the fractions contain cells capable of differentiating into neural cells. It is unclear whether the differentiation of cells contained in the cell fractions provided by the present invention into neural cells is caused by the transformation of so-called hematopoietic cells into neural cells, or, alternatively, by the differentiation of immature cells capable of differentiating into neural cells that are comprised in bone marrow cells, etc. However, the majority of the cells differentiating into neural cells are assumed to be stem or precursor cells, namely, cells having the self-renewal ability and pluripotency. Alternatively, the cells differentiating into neural cells may be stem or precursor cells which have differentiated to some extent into endoderm or mesoderm.
- a cell fraction of the present invention is derived from vertebrate, preferably from mammal (for example, mouse, rat, human, etc.).
- a cell fraction of the present invention can be prepared by subjecting bone marrow cells or cord blood cells collected from vertebrate to density-gradient centrifugation at 2,000 rpm in a solution for a sufficient time-ensuring separation depending on specific gravity, and then recovering the cell fraction with a certain specific gravity within the range of 1.07 to 1.1 g/ml.
- a sufficient time ensuring separation depending on specific gravity refers to a time sufficient for the cells to shift to a position in the solution according to their specific gravity, which is typically about 10 to 30 minutes.
- the specific gravity of the cell fraction to be recovered is within the range of 1.07 to 1.08 g/ml (for example, 1.077 g/ml). Solutions, such as Ficoll solution and Percoll solution, can be used for the density-gradient centrifugation, but is not limited thereto.
- bone marrow (5 to 10 ⁇ l) collected from a vertebrate is combined with a solution (2 ml L-15 plus 3 ml Ficoll), and then centrifuged at 2,000 rpm for 15 minutes to isolate a mononuclear cell fraction (approx. 1 ml)
- the mononuclear cell fraction is combined with culture solution (2 ml NPBM) to wash the cells, and then the cells are again centrifuged at 2,000 rpm for 15 minutes. Then, the precipitated cells are recovered after the removal of the supernatant.
- sources to obtain a cell fraction of the present invention include sternum, and ilium constituting the pelvis. Any other bone can serve as a source so long as it is large enough.
- a cell fraction of the present invention can also be prepared from bone marrows and cord blood stored in bone marrow bank or cord blood bank.
- cell fractions of the present invention includes a mononuclear cell fraction isolated and purified from bone marrow cells or cord blood cells, which contains mesodermal (mesenchymal) stem cells capable of differentiating into neural cells.
- mesodermal (mesenchymal) stem cell refers to cells that can copy (divide and proliferate) cells with the same potential as themselves and that are capable of differentiating into any type of cells constituting mesodermal (mesenchymal) tissues.
- Mesodermal (mesenchymal) cells indicate cells constituting tissues that are embryologically categorized to the mesoderms, including blood cells.
- the mesodermal (mesenchymal) stem cell includes, for example, cells characterized by SH2(+), SH3(+), SH4(+), CD29(+), CD44(+), CD14( ⁇ ), CD34( ⁇ ), and CD45( ⁇ ).
- a cell fraction containing mesodermal (mesenchymal) stem cells can be obtained, for example, by selecting cells having a cell surface marker, such as SH2, as described above from the above-mentioned cell fraction obtained by centrifuging bone marrow cells or cord blood cells (the cell fraction according to claim 2 ).
- a cell fraction containing mesodermal (mesenchymal) stem cells capable of differentiating into neural cells can be prepared by subjecting bone marrow cells or cord blood cells collected from vertebrate to density-gradient centrifugation at 900 G in a solution for a sufficient time ensuring separation depending on specific gravity, and then recovering the cell fraction with a certain specific gravity within the range of 1.07 to 1.1 g/ml.
- a sufficient time ensuring separation depending on specific gravity refers to a time sufficient for the cells to shift to a specific position corresponding to their specific gravity in the solution for density-gradient centrifugation, which is typically about 10 to 30 minutes.
- the specific gravity of a cell fraction to be recovered varies depending on the type of animal (for example, human, rat, and mouse) from which the cells have been derived.
- a solution to be used for density-gradient centrifugation includes Ficoll solution and Percoll solution, but is not limited thereto.
- bone marrow (25 ml) or cord blood collected from vertebrate is combined with an equal volume of PBS solution, and then centrifuge at 900 G for 10 minutes.
- a 5-ml aliquot thereof is combined with Percoll solution (1.073 g/ml), and centrifuged at 900 G for 30 minutes to extract a mononuclear cell fraction.
- the extracted mononuclear cell fraction is combined with a culture solution (DMEM, 10% FBS, 1% antibiotic-antimycotic solution) to wash the cells, and is centrifuged at 2,000 rpm for 15 minutes.
- DMEM 10% FBS, 1% antibiotic-antimycotic solution
- a cell fraction of the present invention is a fraction of mononuclear cells isolated from bone marrow cells or cord blood cells, which contains stromal cells capable of differentiating into neural cells.
- stromal cell include cells characterized by Lin( ⁇ ), Sca-1(+), CD10(+), CD11D(+), CD44(+), CD45(+), CD71(+), CD90(+), CD105(+), CDW123(+), CD127(+), CD164(+), fibronectin (+), ALPH(+), and collagenase-1(+).
- a cell fraction containing stromal cells can be prepared, for example, by selecting cells having a cell surface marker, such as Lin as described above, from the above-mentioned cell fraction obtained by centrifuging bone marrow cells or cord blood cells (the cell fraction according to claim 2 ).
- such a cell fraction can be prepared by subjecting bone marrow cells or cord blood cells collected from vertebrate to density-gradient centrifugation at 800 G in a solution for a sufficient time ensuring separation depending on specific gravity, and then recovering the cell fraction with a certain specific gravity within the range of 1.07 to 1.1 g/ml.
- a sufficient time ensuring separation depending on the specific gravity indicates a time sufficient for the cells to shift to a specific position corresponding to their specific gravity in the solution for density-gradient centrifugation, which is typically about 10 to 30 minutes.
- the specific gravity of a cell fraction to be recovered is preferably within the range of 1.07 to 1.08 g/ml (for example, 1.077 g/ml).
- a solution to be used for density-gradient centrifugation includes Ficoll solution and Percoll solution, but is not limited thereto.
- bone marrow or cord blood collected from vertebrate is combined with an equal volume of a solution (PBS, 2% BSA, 0.6% sodium citrate, and 1% penicillin-streptomycin).
- a 5-ml aliquot thereof is combined with Ficoll+Paque solution (1.077 g/ml) and centrifuged at 800 G for 20 minutes to obtain a mononuclear cell fraction.
- the mononuclear cell fraction is combined with a culture solution (Alfa MEM, 12.5% FBS, 12.5% horse serum, 0.2% i-inositol, 20 mM folic acid, 0.1 mM 2-mercaptoethanol, 2 mM L-glutamine, 1 ⁇ M hydrocortisone, 1% antibiotic-antimycotic solution) to wash the cells, and then are centrifuged at 2,000 rpm for 15 minutes. The supernatant is removed after centrifugation. The precipitated cells are collected and then cultured at 37° C. under 5% CO 2 atmosphere.
- a culture solution Alfa MEM, 12.5% FBS, 12.5% horse serum, 0.2% i-inositol, 20 mM folic acid, 0.1 mM 2-mercaptoethanol, 2 mM L-glutamine, 1 ⁇ M hydrocortisone, 1% antibiotic-antimycotic solution
- a cell fraction of the present invention is a mononuclear cell fraction containing cells characterized by AC133(+) capable of differentiating into neural cells, which is isolated from bone marrow cells, cord blood cells, or embryonic hepatic tissues.
- a cell fraction can be obtained, for example, by selecting cells having a cell surface marker including the above-mentioned AC133(+) from the cell fraction obtained, as described above, by centrifuging bone marrow cells or cord blood cells (the cell fraction according to claim 2 ).
- the cell fraction can be obtained by subjecting embryonic hepatic tissues collected from vertebrate to density-gradient centrifugation at 2,000 rpm in a solution for a sufficient time ensuring separation depending on specific gravity, recovering a cell fraction within the range of a specific gravity of 1.07 to 1.1 g/ml, and then recovering cells with the characteristic of AC133(+) from the cell fraction.
- a sufficient time ensuring separation depending on specific gravity indicates a time sufficient for the cells to shift to a specific position corresponding to their specific gravity in the solution for density-gradient centrifugation, which is typically about 10 to 30 minutes.
- the solution to be used for density-gradient centrifugation includes Ficoll solution and Percoll solution, but is not limited thereto.
- liver tissue collected from vertebrate is washed in L-15 solution, and then treated enzymatically in an L-15 solution containing 0.01% DNaseI, 0.25% trypsin, and 0.1% collagenase at 37° C. for 30 minutes. Then, the tissue is dispersed into single cells by pipetting.
- the single-dispersed embryonic hepatic cells are centrifuged by the same procedure as described for the preparation of the mononuclear cell fraction from femur in Example 1 (1).
- the cells thus obtained are washed, and then AC133(+) cells are collected from the washed cells using an AC133 antibody.
- AC133(+) cells are collected from embryonic hepatic tissues.
- the antibody-based recovery of AC133(+) cells can be achieved using magnetic beads or a cell sorter (FACS, etc.).
- the above-mentioned cell fraction containing mesenchymal stem cells can engraft favorably and differentiate into neural cells such as neurons or glia when transplanted into a stroke model or a cerebral infarction model.
- the present invention also provides cells capable of differentiating into neural cells, which are contained in the above-mentioned cell fraction.
- These cells include, for example, neural stem cells, mesodermal stem cells, mesenchymal stem cells, stromal cells, and AC133-positive cells which are contained in the above-mentioned cell fraction, but are not limited thereto so long as they can differentiate into neural cells.
- the present invention also provides compositions for treating neurological diseases, which comprise a cell fraction or cells of the present invention. It is possible, to transplant the cell fractions or cells of the present invention without modification. However, in order to improve the efficiency of therapy, they may be transplanted as compositions combined with various additives or introduced with genes.
- compositions of the present invention may comprise, for example, (1) addition of a substance that improves the proliferation rate of cells included in a cell fraction of the present invention or enhances the differentiation of the cells into neural cells, or introducing a gene having the same effect; (2) addition of a substance that improves the viability of cells in a cell fraction of the present invention in damaged neural tissues, or introducing a gene having the same effect; (3) addition of a substance that inhibits adverse effects of damaged neural tissue on the cells in a cell fraction of the present invention, or introducing a gene having the same effect; (4) addition of a substance that prolongs the lifetime of donor cells, or introducing a gene having the same effect; (5) addition of a substance that modulates the cell cycle, or introducing a gene having the same effect; (6) addition of a substance to suppress the immunoreaction or inflammation, or introducing a gene having the same effect; (7) addition of a substance that enhances the energy metabolism, or introducing a gene having the same effect; (8) addition of a substance that improves the
- the cells according to the present invention are immobilized in the bone marrow by a distinct mechanism involving a certain type of substance (proteins, etc.) and do not normally move out into the peripheral blood. Therefore, to make these cells enter the peripheral blood circulation, conventionally, they are removed from the bone marrow, and then administered intravenously.
- the studies conducted by the present inventors gradually elucidated the mechanism of immobilization of these cells in the bone marrow.
- the discovery made by the present inventors showed that these cells, which had been localized in the bone marrow, could be made to move out into the peripheral blood by intravenous injection of active factors, such as an antibody, a cytokine, chemicals, or a growth factor. That is, therapeutic effect of bone marrow transplantation that is similar to that of the aforementioned method can be expected from intravenous injection of an active factor, such as an antibody, a cytokine, chemicals, or a growth factor.
- a cell fraction, cell, and composition of the present invention can be used for treating neurological diseases.
- Target neurological diseases for the therapy include, for example, central and peripheral demyelinating diseases; central and peripheral degenerative diseases; cerebral apoplexy (including cerebral infarction, cerebral hemorrhage, and subarachnoid hemorrhage); cerebral tumor; disorders of higher brain function including dementia; psychiatric diseases; epilepsy, traumatic neurological diseases (including head injury, cerebral contusion, and spinal cord injury); infectious diseases; and infarction of spinal cord, but are not limited thereto.
- cells derived from bone marrow cells of a recipient can be transplanted as donor cells (autotransplantation therapy).
- autotransplantation therapy has the following advantages: (1) low risk of rejection for the transplantation; and (2) no difficulty in using immunosuppressant.
- cells derived from other person or nonhuman animal may be used.
- Cells frozen for storage are also usable.
- the donor cells may be derived from cord blood.
- Bone marrow can be collected, for example, by anesthetizing (by local or systemic anesthesia) an animal (including human) that serves as a source, put a needle into the sternum or iliac of the animal, and aspirating the bone marrow with a syringe.
- anesthetizing by local or systemic anesthesia
- an animal including human
- it is an established technique to collect cord blood at birth by putting needle directly into the umbilical cord, and aspirating the blood from the umbilical cord using syringe, and to store the blood.
- Transplantation of cells into a patient can be performed, for example, by first filling a syringe with cells to be transplanted.
- the cells are suspended in an artificial cerebrospinal fluid or physiological saline.
- the damaged neural tissue is exposed by surgery, and, with a needle, directly injecting the cells into the lesion.
- Due to high migrating potential of cells contained in a cell fraction of the present invention they can migrate in the neural tissues.
- cells can be transplanted into a region adjacent to the lesion.
- injection of the cells into the cerebrospinal fluid is also expected to be efficacious.
- the cells can be injected into a patient by typical lumbar puncture, without surgical operation only under local anesthetization.
- the patient can be treated in patient's sickroom (not in an operation room), which makes the method preferable.
- intravenous injection including any systemic transplantations such as intravenous, intraarterial, selective intraarterial administration
- transplantation can be carried out by a procedure based on typical blood transfusion, which is advantageous in that the treatment can be performed in patient's sickroom.
- cells in a cell fraction of the present invention can be used as a carrier (vector) for genes.
- the cells are expected to be useful as a vector for gene therapy for various neurological diseases such as brain tumor.
- FIG. 1 shows optical light micrographs of transections of dorsal column of the spinal cord, which had been prepared at 1-mm intervals.
- FIG. 2 shows microphotographs demonstrating the remyelination of rat spinal cord (A), after transplantation of adult mouse bone marrow cells; and (C), after transplantation of Schwann cells. Photomicrographs demonstrating remyelinated axon observed at higher magnification are shown in (B), after transplantation of bone marrow cells; and (D), after transplantation of Schwann cells. Scale bars: 250 ⁇ m in (A) and (C); 10 ⁇ m in (B) and (D).
- FIG. 3 shows an electron micrograph of remyelinated axon after the transplantation of bone marrow into the dorsal columns.
- the tissue was treated with substrate X-Gal to detect transplanted bone marrow cells containing the P-galactosidase gene in the damaged tissues (the reaction product is indicated with arrow).
- Basal lamina was found around the fibers (wedge-shaped mark; scale bar 1 ⁇ m). The presence of large cytoplasmic and nuclear regions and basal lamina in the transplanted cells indicates peripheral myelination.
- Mouse bone marrow cells (10 ⁇ l) were obtained from the femur of adult LacZ (a structural gene of ⁇ -galactosidase) transgenic mice (The Jackson Laboratory, Maine, USA). The collected sample was diluted in L-15 medium (2 ml) containing 3 ml Ficoll, and centrifuged at 2,000 rpm for 15 minutes. Cells were collected from the mononuclear cell fraction, and suspended in 2 ml serum-free medium (NPMM: Neural Progenitor cell Maintenance Medium). Following centrifugation (2,000 rpm, 15 min), the supernatant was removed, and precipitated cells were collected and re-suspended in NPMM.
- L-15 medium 2 ml
- NPMM Neural Progenitor cell Maintenance Medium
- rats were anesthetized as above, and aseptic laminectomy of the eleventh thoracic spine (T-11) was conducted.
- a demyelinating lesion was generated by the direct injection of ethidium bromide (EB) into the dorsal columns via a glass micropipette whose end was drawn.
- EB ethidium bromide
- 0.5 ⁇ l saline containing 0.3 mg/ml EB was injected at the depths of 0.7 and 0.4 mm.
- Rats were deeply anesthetized by the administration of sodium pentobarbital (60 mg/kg, i.p.), and perfused through the heart cannula, first, with phosphate-buffer solution (PBS) and then with a fixative containing 2% glutaraldehyde and 2% paraformaldehyde in 0.14 M Sorensen's phosphate buffer, pH 7.4. Following in situ fixation for 10 minutes, the spinal cord was carefully excised, cut into 1 mm segments and kept in fresh fixative.
- PBS phosphate-buffer solution
- the tissue was washed several times in Sorensen's phosphate buffer, post-fixed in 1% OsO 4 for 2 hours at 25° C., dehydrated by elevating the concentration of the ethanol solution, passed through propylene oxide and embedded in EPON. Then, the tissue was cut into sections (1 ⁇ m), counterstained with 0.5% methylene blue and 0.5% azure II in 0.5% borax, and examined under light microscope (Zeiss: Axioskop FS). Ultrathin sections were counterstained with uranyl and lead salts, and examined with JEOL JEM1200EX electron microscope (JEOL, Ltd., Japan) at 60 kV.
- a 50 ⁇ 50 ⁇ m standardized region in the central core of the dorsal columns in the spinal cords near the site wherein the cells were initially injected was used for morphometric analysis.
- the numbers of remyelinated axons and cell bodies associated with the axons were counted within this region; and the density to square millimeters was calculated.
- the dorsal column in the spinal cord mostly consists of myelinated axons ( FIG. 1A , B).
- the proliferation of endogenous glial cells was inhibited by the irradiation of X-ray to the dorsal columns of the lumbar spinal cord.
- a nucleic acid chelator ethidium bromide
- glial cells such as oligodendrocytes were found damaged and local demyelination occurred.
- Such lesions generated according to this procedure are characterized by almost complete loss of endogenous glial cells (astrocytes and oligodendrocytes) and preservation of axons ( FIG. 1C ).
- FIGS. 2A and 2B Three weeks after transplantation of LacZ transgenic mouse bone marrow cells (BM) into the central region of the lesion in immunosuppressed and demyelinated rat models, extensive remyelination of the demyelinated axons was observed ( FIGS. 2A and 2B ). Remyelination was observed across the entire coronal dimension of the dorsal columns and throughout the antero-posterior extent of the lesion.
- FIGS. 2C and 2D show the pattern of remyelination observed after transplantation of allogeneic Schwann cells (SC) into the EB-X lesion model. It is remarkable that large nuclear and cytoplasmic regions were found around the remyelinated axons, a characteristic of peripheral myelin, by both BM and SC transplantations.
- SC allogeneic Schwann cells
- ⁇ -galactosidase expressing myelin-forming cells were detected in vivo.
- Spinal cords were collected and fixed in 0.5% glutaraldehyde in phosphate-buffer for 1 h.
- Sections (100 ⁇ m) were cut with a vibratome and ⁇ -galactosidase expressing myelin-forming cells were detected by incubating the sections at 37° C.
- X-Gal substrate which reacts with ⁇ -galactosidase to develop color
- X-Gal developer 35 mM K 3 Fe(CN) 6 /35 mM K 4 Fe(CN) 6 3H 2 O/2 mM MgCl 2 in phosphate-buffered saline
- Sections were then fixed for an additional 3 h in 3.6% (vol/vol) glutaraldehyde in phosphate-buffer (0.14 M), and were examined with light microscope for the presence of blue reaction product ( ⁇ -galactosidase reaction product).
- the tissue Prior to embedding in EPON, the tissue was treated with 1% OsO 4 , dehydrated in a graded series of ethanol, and soaked in propylene oxide for a short period. Ultrathin sections were then examined under an electron microscope without further treatment.
- the present inventors isolated mesenchymal stem cells with the characteristic of cell markers SH2(+), SH3(+), CD29(+), CD44(+), CD14( ⁇ ), CD34( ⁇ ), and CD45( ⁇ ) from the cell fraction obtained in Example 1 (1). Furthermore, they discovered that transplantation of the cells into the demyelinated regions of rat spinal cord results in more efficient remyelination. It was also revealed that the cells survived favorably and differentiated into neurons or neuronal cells and glia cells when transplanted into cerebral infarction model rats.
- the present inventors isolated stromal cells characterized by the cell surface markers Lin ( ⁇ ), Sca-1(+), CD10(+), CD11D (+), CD44(+), CD45(+), CD71(+), CD90(+), CD105(+), CDW123(+), CD127(+), CD164(+), fibronectin (+), ALPH (+), and collagenase-1(+) from the cell fraction obtained in Example 1 (1). Transplantation of the cells into demyelinated regions of rat spinal cord also resulted in efficient remyelination.
- the present inventors isolated cells characterized by the cell surface marker AC133(+) from the cell fraction obtained in Example 1 (1). Transplantation of the cells into demyelinated regions of rat spinal cord also resulted in efficient remyelination.
- the present inventors obtained a cell fraction containing AC133-positive cells capable of differentiating into neural cells from rat embryonic hepatic tissues by the following procedure. Specifically, first, liver tissues collected from rat fetuses were washed in L-15 solution, and then treated enzymatically in L-15 solution containing 0.01% DNaseI, 0.25% trypsin, and 0.1% collagenase at 37° C. for 30 minutes. Then, the tissue was dispersed into single cells by pipetting several times. The single-dispersed embryonic hepatic tissues were centrifuged as in Example 1 (1) (preparation of mononuclear cell fraction from femur) to isolate a mononuclear cell fraction.
- the obtained mononuclear cell fraction was washed, and then, AC133(+) cells were recovered from the cell fraction using anti-AC133 antibody.
- the isolation of AC133-positive cells can be achieved using magnetic beads or a cell sorter (FACS or the like). Transplantation of the obtained AC133-positive cells into demyelinated regions of rat spinal cord also resulted in efficient remyelination.
- the present invention provides fractions of mononuclear cells isolated and purified by collecting bone marrow-derived bone marrow cells, cord blood-derived cells, or fetal liver-derived cells. Transplantation of such mononuclear cell fractions into a demyelination model animal was confirmed to result in remyelination of the demyelinated axon.
- Cells for transplantation can be relatively easily isolated from a small quantity of bone marrow cell fluid aspirated from bone marrow, and can be prepared for transplantation in several tens of minutes after the cells are being collected. Thus, these cells can serve as useful and regenerable cellular material for autotransplantation in the treatment of demyelinating diseases.
- This invention highlights the development of the autotransplantation technique to treat demyelinating diseases in the central nervous system. Furthermore, the use of the present invention in transplantation and regeneration therapy for more general and diffuse damage in the nervous system is envisaged. In other words, this invention sheds light on autotransplantation therapy against ischemic cerebral damage, traumatic cerebral injury, cerebral degenerating diseases, and metabolic neurological diseases in the central and peripheral nervous systems.
- cells in the hematopoietic system are used as donor cells.
- the cells may be transplanted into the vessels instead of directly transplanting them into neural tissues.
- donor cells transplanted into a vessel can migrate to the neural tissues and thereby regenerate the neural tissues.
- the present invention adds significantly to elucidate the mechanism underlying the differentiation of non-neural cells such as hematopoietic cells and mesenchymal, cells into neural cells.
- non-neural cells such as hematopoietic cells and mesenchymal cells
- use of such genes will allow efficient transformation of a sufficient quantity of non-neural cells such as hematopoietic cells and mesenchymal cells in a living body to neural cells.
- the present invention is a breakthrough in the field of “gene therapy” for inducing regeneration of neural tissues.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Developmental Biology & Embryology (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Rheumatology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Hematology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Psychiatry (AREA)
- Dermatology (AREA)
- Reproductive Health (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
Abstract
Demyelinated axons were remyelinated in the demyelinated rat model by collecting bone marrow cells from mouse bone marrow and transplanting the mononuclear cell fraction separated from these bone marrow cells.
Description
- The present invention relates to cells derived from bone marrow cells, cord blood cells, or embryonic hepatic tissues that can differentiate into neural cells, and cell fractions containing such cells. It is expected that these cells and cell fractions can be used to treat neurological diseases, particularly in autologous transplantation therapy.
- Transplantation of oligodendrocytes (i.e., oligodendroglia) (Archer D. R., et al., 1994. Exp. Neurol. 125:268-77; Blakemore W. F., Crang A. J., 1988. Dev. Neurosci. 10:1-11; Gumpel M., et al. 1987. Ann. New York Acad. Sci. 495:71-85) or myelin-forming cells, such as Schwann cells (Blakemore W. F., 1977. Nature 266:68-9; Blakemore W. F., Crang A. J., 1988. Dev. Neurosci. 10:1-11; Honmou O. et al., 1996. J. Neurosci. 16:3199-208), or olfactory ensheating cells (Franklin R. J. et al., 1996. Glia 17:217-24; Imaizumi T. et al., 1998. J. Neurosci. 18(16):6176-6185; Kato T. et al., 2000. Glia 30:209-218), can elicit remyelination in animal models and recovery of electrophysiological function (Utzschneider D. A. et al., 1994. Proc. Natl. Acad. Sci. USA. 91:53-7; Honmou O. et al., 1996. J. Neurosci. 16:3199-208). It is possible to prepare such cells from patients or other persons for cell therapy. However, this method is considerably problematic because tissue material must be collected from either the brain or nerves.
- Neural progenitor cells or stem cells derived from brain have the ability to self-renewal and differentiate into various lineages of neurons and glia cells (Gage F. H. et al., 1995. Proc. Natl. Acad. Sci. USA. 92:11879-83; Lois C., Alvarez-Buylla A., 1993. Proc. Natl. Acad. Sci. USA. 90:2074-7; Morshead C. M. et al., 1994. Neuron 13:1071-82; Reynolds B. A., Weiss S., 1992. Science 255:1707-10). By transplantation into newborn mouse brain, human neural stem cells collected from fetal tissues differentiate into neurons and astrocytes (Chalmers-Redman R. M. et al., 1997. Neurosci. 76:1121-8; Moyer M. P. et al., 1997. Transplant. Proc. 29:2040-1; Svendsen C. N. et al., 1997. Exp. Neurol. 148:135-46), and myelinate the axons (Flax J. D. et al., 1998. Nat. Biotechnol. 16:1033-9). Remyelination and recovery of impulse conduction upon transplantation of neural progenitor (stem) cells derived from adult human brain into demyelinated rodent spinal cord have been reported (Akiyama Y. et al., 2001. Exp. Neurol.).
- These studies have evoked great interest due to the indicated possibility of the application of the above-mentioned cells to regenerative strategy of neurological diseases (Akiyama Y. et al., 2001. Exp. Neurol.; Chalmers-Redman R. M. et al., 1997. Neurosci. 76:1121-8; Moyer M. P. et al., 1997. Transplant. Proc. 29:2040-1; Svendsen C. N. et al., 1997. Exp. Neural. 148:135-46; Yandava B. D. et al., 1999. Proc. Natl. Acad. Sci. USA. 96:7029-34). However, in order to establish cell transplantation therapy (including autologous transplantation) using these cells, still problems, such as establishment of harvest method and requirement of cell expansion using trophic factors, remain to be solved.
- According to the recent studies, neural stem cells were revealed to be able to differentiate or transform into hematopoietic cells in vivo, suggesting that neural progenitor (stem) cells are not restricted to the neural cell lineage (Bjornson C. R. et al., 1999. Science 283:534-7). Furthermore, bone marrow stromal cells (not mesenchymal stem cells in the bone marrow) are reported to differentiate into astrocytes by the injection into the lateral ventricles of neonatal mice (Kopen G. C. et al., Proc. Natl. Acad. Sci. USA. 96:10711-6), and into neurons in vitro when cultured under appropriate cell culture conditions (Woodbury D. et al., 2000. J. Neurosci. Res. 61:364-70).
- The present inventors have previously isolated and cultured neural stem cells from adult human brain, and established some cell lines. By studying their functions, the inventors newly discovered that the neural stem cells have pluripotency and the ability to self-renewal. Specifically, single-cell expansion of neural progenitor (stem) cells obtained from adult human brain was conducted to establish cell lines; the established cells were then subjected to in vitro clonal analysis. The result showed that the cell lines had pluripotency (namely, differentiation into neuron, astroglia (or astrocyte), and oligodendroglia (i.e., oligodendrocyte)) and the ability to self-renewal (namely, proliferation potency). Thus, these cells were confirmed to possess the characteristics of neural stem cell.
- Transplantation of these cells indeed resulted in very favorable graft survival, migration, and differentiation in cerebral ischemic model rats or injury model rats. Furthermore, transplantation of the cells was found to result in functional myelin sheath formation in spinal cord demyelination model rats. Thus, such transplantation allows remyelination of the demyelinated axon and restoration of the neural function in the rat spinal cord demyelination model. Effectiveness of such transplantation therapy using these cells was confirmed by histological, electrophysiological, and behavior studies.
- Judging from the above-described findings, transplantation of cultured neural stem cells, which have been isolated from a small amount of neural tissue collected from the cerebrum of a patient, into the lesion of the brain or the spinal cord of the patient seems to be a widely applicable in autotransplantation therapy.
- However, while not causing neurologic deficits, collecting tissues containing neural stem cells from cerebrum is relatively invasive. Thus, considering the need for establishing therapeutic methods for various complicated diseases in the nervous system today, it is crucial to establish a safer and simpler method for autotransplantation therapy.
- Thus, an objective of the present invention is to provide cellular material that is useful in the treatment of neurological diseases, and which can be prepared safely and readily. Another objective of the present invention is to provide a method for treating neurological diseases, preferably a method for autotransplantation therapy, using the cellular material.
- In view of the existing state as described above, to establish donor cells the present inventors focused on the technique of collecting bone marrow cells from bone marrow, a simpler technique as compared to the collection of neural stem cells and routinely used in today's medical practice. First, they collected bone marrow cells from mouse bone marrow, isolated mononuclear cell fraction, and then transplanted this fraction as donor cells into spinal cord demyelination model rats. Surprisingly, it was discovered that the demyelinated axon gets remyelination by the treatment. Hence, the present inventors newly revealed that the mononuclear cell fraction prepared from bone marrow cells have the ability to differentiate into neural cells. The present inventors also discovered that cell fractions containing mesodermal stem cells, mesenchymal stem cell, stromal cells, and AC133-positive cells, that were isolated from the mononuclear cell fraction had the ability to differentiate into neural cells. Besides bone marrow cells, these cell fractions can also be prepared from cord blood cells. Furthermore, AC133-positive cells can be prepared from embryonic hepatic tissues.
- Thus, the present invention provides cell fractions containing cells capable of differentiating into neural cells, which are isolated from bone marrow cells, cord blood cells, and embryonic hepatic tissues.
- In another embodiment, such cell fractions contain mesenchymal stem cells having the following character: SH2(+), SH3(+), SH4(+), CD29(+), CD44(+), CD14(−), CD34(−), and CD45(−).
- In another embodiment, such cell fractions contain stromal cells having the following characteristics: Lin(−), Sca-1(+), CD10(+), CD11D(+), CD44(+), CD45(+), CD71(+), CD90(+), CD105(+), CDW123(+), CD127(+), CD164(+), fibronectin (+), ALPH (+), and collagenase-1(+).
- In another embodiment, such cell fractions contain cells having the character AC133(+).
- In addition, the present invention provides cells capable of differentiating into neural cells, which are contained in the above-mentioned cell fraction.
- Furthermore, the present invention provides compositions for treating neurological disease, which contain the above-mentioned mononuclear cell fractions or the above-mentioned cells. According to a preferred embodiment of the present invention, the neurological disease is selected from the group consisting of: central and peripheral demyelinating diseases; central and peripheral degenerative diseases; cerebral apoplexy (cerebral infarction, cerebral hemorrhage, subarachnoid hemorrhage); brain tumor; dysfunction of higher function of the brain (the term “higher function of the brain” involves the cognitive function, short and long memory, speech, etc.); psychiatric diseases; dementia; infectious diseases; epilepsy; traumatic neurological diseases; and infarction of spinal cord diseases.
- Furthermore, the present invention provides therapeutic methods for neurological diseases, which comprises transplanting of the above-mentioned mononuclear cell fractions, cells, or compositions. In preferred embodiments, the donor cells are derived from a recipient.
- The present invention provides mononuclear cell fractions isolated from bone marrow cells, cord blood cells, or embryonic hepatic tissues, wherein the fractions contain cells capable of differentiating into neural cells. It is unclear whether the differentiation of cells contained in the cell fractions provided by the present invention into neural cells is caused by the transformation of so-called hematopoietic cells into neural cells, or, alternatively, by the differentiation of immature cells capable of differentiating into neural cells that are comprised in bone marrow cells, etc. However, the majority of the cells differentiating into neural cells are assumed to be stem or precursor cells, namely, cells having the self-renewal ability and pluripotency. Alternatively, the cells differentiating into neural cells may be stem or precursor cells which have differentiated to some extent into endoderm or mesoderm.
- Cells in a cell fraction of the present invention do not have to be proliferated with any trophic factors (then again they can proliferate in the presence of trophic factors). Thus, these cells are simple and practical from the standpoint of the development of autotransplantation technique for the diseases in the neural, and are very beneficial in medical industry. In general, a cell fraction of the present invention is derived from vertebrate, preferably from mammal (for example, mouse, rat, human, etc.).
- A cell fraction of the present invention can be prepared by subjecting bone marrow cells or cord blood cells collected from vertebrate to density-gradient centrifugation at 2,000 rpm in a solution for a sufficient time-ensuring separation depending on specific gravity, and then recovering the cell fraction with a certain specific gravity within the range of 1.07 to 1.1 g/ml. Herein, the phrase “a sufficient time ensuring separation depending on specific gravity” refers to a time sufficient for the cells to shift to a position in the solution according to their specific gravity, which is typically about 10 to 30 minutes. The specific gravity of the cell fraction to be recovered is within the range of 1.07 to 1.08 g/ml (for example, 1.077 g/ml). Solutions, such as Ficoll solution and Percoll solution, can be used for the density-gradient centrifugation, but is not limited thereto.
- Specifically, first, bone marrow (5 to 10 μl) collected from a vertebrate is combined with a solution (2 ml L-15 plus 3 ml Ficoll), and then centrifuged at 2,000 rpm for 15 minutes to isolate a mononuclear cell fraction (approx. 1 ml) The mononuclear cell fraction is combined with culture solution (2 ml NPBM) to wash the cells, and then the cells are again centrifuged at 2,000 rpm for 15 minutes. Then, the precipitated cells are recovered after the removal of the supernatant. Besides femur, sources to obtain a cell fraction of the present invention include sternum, and ilium constituting the pelvis. Any other bone can serve as a source so long as it is large enough. A cell fraction of the present invention can also be prepared from bone marrows and cord blood stored in bone marrow bank or cord blood bank.
- Another embodiment of cell fractions of the present invention includes a mononuclear cell fraction isolated and purified from bone marrow cells or cord blood cells, which contains mesodermal (mesenchymal) stem cells capable of differentiating into neural cells. The term “mesodermal (mesenchymal) stem cell” refers to cells that can copy (divide and proliferate) cells with the same potential as themselves and that are capable of differentiating into any type of cells constituting mesodermal (mesenchymal) tissues. Mesodermal (mesenchymal) cells indicate cells constituting tissues that are embryologically categorized to the mesoderms, including blood cells. The mesodermal (mesenchymal) stem cell includes, for example, cells characterized by SH2(+), SH3(+), SH4(+), CD29(+), CD44(+), CD14(−), CD34(−), and CD45(−). A cell fraction containing mesodermal (mesenchymal) stem cells can be obtained, for example, by selecting cells having a cell surface marker, such as SH2, as described above from the above-mentioned cell fraction obtained by centrifuging bone marrow cells or cord blood cells (the cell fraction according to claim 2).
- Furthermore, a cell fraction containing mesodermal (mesenchymal) stem cells capable of differentiating into neural cells can be prepared by subjecting bone marrow cells or cord blood cells collected from vertebrate to density-gradient centrifugation at 900 G in a solution for a sufficient time ensuring separation depending on specific gravity, and then recovering the cell fraction with a certain specific gravity within the range of 1.07 to 1.1 g/ml. Herein, “a sufficient time ensuring separation depending on specific gravity” refers to a time sufficient for the cells to shift to a specific position corresponding to their specific gravity in the solution for density-gradient centrifugation, which is typically about 10 to 30 minutes. The specific gravity of a cell fraction to be recovered varies depending on the type of animal (for example, human, rat, and mouse) from which the cells have been derived. A solution to be used for density-gradient centrifugation includes Ficoll solution and Percoll solution, but is not limited thereto.
- Specifically, first, bone marrow (25 ml) or cord blood collected from vertebrate is combined with an equal volume of PBS solution, and then centrifuge at 900 G for 10 minutes. Precipitated cells are mixed with PBS and then are recovered (cell density=approx. 4×107 cells/ml) to remove blood components. Then, a 5-ml aliquot thereof is combined with Percoll solution (1.073 g/ml), and centrifuged at 900 G for 30 minutes to extract a mononuclear cell fraction. The extracted mononuclear cell fraction is combined with a culture solution (DMEM, 10% FBS, 1% antibiotic-antimycotic solution) to wash the cells, and is centrifuged at 2,000 rpm for 15 minutes. Finally, the supernatant is removed, precipitated cells are recovered and cultured at 37° C. under 5% CO2 atmosphere.
- Another embodiment of a cell fraction of the present invention is a fraction of mononuclear cells isolated from bone marrow cells or cord blood cells, which contains stromal cells capable of differentiating into neural cells. Examples of stromal cell include cells characterized by Lin(−), Sca-1(+), CD10(+), CD11D(+), CD44(+), CD45(+), CD71(+), CD90(+), CD105(+), CDW123(+), CD127(+), CD164(+), fibronectin (+), ALPH(+), and collagenase-1(+). A cell fraction containing stromal cells can be prepared, for example, by selecting cells having a cell surface marker, such as Lin as described above, from the above-mentioned cell fraction obtained by centrifuging bone marrow cells or cord blood cells (the cell fraction according to claim 2).
- Furthermore, such a cell fraction can be prepared by subjecting bone marrow cells or cord blood cells collected from vertebrate to density-gradient centrifugation at 800 G in a solution for a sufficient time ensuring separation depending on specific gravity, and then recovering the cell fraction with a certain specific gravity within the range of 1.07 to 1.1 g/ml. Herein, “a sufficient time ensuring separation depending on the specific gravity” indicates a time sufficient for the cells to shift to a specific position corresponding to their specific gravity in the solution for density-gradient centrifugation, which is typically about 10 to 30 minutes. The specific gravity of a cell fraction to be recovered is preferably within the range of 1.07 to 1.08 g/ml (for example, 1.077 g/ml). A solution to be used for density-gradient centrifugation includes Ficoll solution and Percoll solution, but is not limited thereto.
- Specifically, first, bone marrow or cord blood collected from vertebrate is combined with an equal volume of a solution (PBS, 2% BSA, 0.6% sodium citrate, and 1% penicillin-streptomycin). A 5-ml aliquot thereof is combined with Ficoll+Paque solution (1.077 g/ml) and centrifuged at 800 G for 20 minutes to obtain a mononuclear cell fraction. The mononuclear cell fraction is combined with a culture solution (Alfa MEM, 12.5% FBS, 12.5% horse serum, 0.2% i-inositol, 20 mM folic acid, 0.1 mM 2-mercaptoethanol, 2 mM L-glutamine, 1 μM hydrocortisone, 1% antibiotic-antimycotic solution) to wash the cells, and then are centrifuged at 2,000 rpm for 15 minutes. The supernatant is removed after centrifugation. The precipitated cells are collected and then cultured at 37° C. under 5% CO2 atmosphere.
- Another embodiment of a cell fraction of the present invention is a mononuclear cell fraction containing cells characterized by AC133(+) capable of differentiating into neural cells, which is isolated from bone marrow cells, cord blood cells, or embryonic hepatic tissues. Such a cell fraction can be obtained, for example, by selecting cells having a cell surface marker including the above-mentioned AC133(+) from the cell fraction obtained, as described above, by centrifuging bone marrow cells or cord blood cells (the cell fraction according to claim 2).
- Furthermore, the cell fraction can be obtained by subjecting embryonic hepatic tissues collected from vertebrate to density-gradient centrifugation at 2,000 rpm in a solution for a sufficient time ensuring separation depending on specific gravity, recovering a cell fraction within the range of a specific gravity of 1.07 to 1.1 g/ml, and then recovering cells with the characteristic of AC133(+) from the cell fraction. Herein, “a sufficient time ensuring separation depending on specific gravity” indicates a time sufficient for the cells to shift to a specific position corresponding to their specific gravity in the solution for density-gradient centrifugation, which is typically about 10 to 30 minutes. The solution to be used for density-gradient centrifugation includes Ficoll solution and Percoll solution, but is not limited thereto.
- Specifically, first, liver tissue collected from vertebrate is washed in L-15 solution, and then treated enzymatically in an L-15 solution containing 0.01% DNaseI, 0.25% trypsin, and 0.1% collagenase at 37° C. for 30 minutes. Then, the tissue is dispersed into single cells by pipetting. The single-dispersed embryonic hepatic cells are centrifuged by the same procedure as described for the preparation of the mononuclear cell fraction from femur in Example 1 (1). The cells thus obtained are washed, and then AC133(+) cells are collected from the washed cells using an AC133 antibody. Thus, cells capable of differentiating into neural cells can be prepared from embryonic hepatic tissues. The antibody-based recovery of AC133(+) cells can be achieved using magnetic beads or a cell sorter (FACS, etc.).
- Transplantation of any of these cell fractions containing mesodermal stem cells, mesenchymal stem cells, stromal cells, or AC133-positive cells into demyelinated spinal cord can lead to efficient remyelination of the demyelinated region. In particular, the above-mentioned cell fraction containing mesenchymal stem cells can engraft favorably and differentiate into neural cells such as neurons or glia when transplanted into a stroke model or a cerebral infarction model.
- The present invention also provides cells capable of differentiating into neural cells, which are contained in the above-mentioned cell fraction. These cells include, for example, neural stem cells, mesodermal stem cells, mesenchymal stem cells, stromal cells, and AC133-positive cells which are contained in the above-mentioned cell fraction, but are not limited thereto so long as they can differentiate into neural cells.
- The present invention also provides compositions for treating neurological diseases, which comprise a cell fraction or cells of the present invention. It is possible, to transplant the cell fractions or cells of the present invention without modification. However, in order to improve the efficiency of therapy, they may be transplanted as compositions combined with various additives or introduced with genes. The preparation of compositions of the present invention may comprise, for example, (1) addition of a substance that improves the proliferation rate of cells included in a cell fraction of the present invention or enhances the differentiation of the cells into neural cells, or introducing a gene having the same effect; (2) addition of a substance that improves the viability of cells in a cell fraction of the present invention in damaged neural tissues, or introducing a gene having the same effect; (3) addition of a substance that inhibits adverse effects of damaged neural tissue on the cells in a cell fraction of the present invention, or introducing a gene having the same effect; (4) addition of a substance that prolongs the lifetime of donor cells, or introducing a gene having the same effect; (5) addition of a substance that modulates the cell cycle, or introducing a gene having the same effect; (6) addition of a substance to suppress the immunoreaction or inflammation, or introducing a gene having the same effect; (7) addition of a substance that enhances the energy metabolism, or introducing a gene having the same effect; (8) addition of a substance that improves the migration of donor cells in host tissues, or introducing a gene having the same effect; (9) addition of a substance that improves blood flow (including inductions of angiogenesis), or introducing a gene having the same effect; (10) addition of a substance that cure the infectious diseases, or introducing a gene having the same effect, or (11) addition of a substance that cure the tumors, or introducing a gene having the same effect, but is not limited thereto.
- It is considered that the cells according to the present invention are immobilized in the bone marrow by a distinct mechanism involving a certain type of substance (proteins, etc.) and do not normally move out into the peripheral blood. Therefore, to make these cells enter the peripheral blood circulation, conventionally, they are removed from the bone marrow, and then administered intravenously. However, the studies conducted by the present inventors gradually elucidated the mechanism of immobilization of these cells in the bone marrow. The discovery made by the present inventors showed that these cells, which had been localized in the bone marrow, could be made to move out into the peripheral blood by intravenous injection of active factors, such as an antibody, a cytokine, chemicals, or a growth factor. That is, therapeutic effect of bone marrow transplantation that is similar to that of the aforementioned method can be expected from intravenous injection of an active factor, such as an antibody, a cytokine, chemicals, or a growth factor.
- A cell fraction, cell, and composition of the present invention can be used for treating neurological diseases. Target neurological diseases for the therapy include, for example, central and peripheral demyelinating diseases; central and peripheral degenerative diseases; cerebral apoplexy (including cerebral infarction, cerebral hemorrhage, and subarachnoid hemorrhage); cerebral tumor; disorders of higher brain function including dementia; psychiatric diseases; epilepsy, traumatic neurological diseases (including head injury, cerebral contusion, and spinal cord injury); infectious diseases; and infarction of spinal cord, but are not limited thereto.
- According to the present invention, cells derived from bone marrow cells of a recipient can be transplanted as donor cells (autotransplantation therapy). This has the following advantages: (1) low risk of rejection for the transplantation; and (2) no difficulty in using immunosuppressant. When autotransplantation therapy is arduous, then cells derived from other person or nonhuman animal may be used. Cells frozen for storage are also usable. The donor cells may be derived from cord blood.
- Bone marrow can be collected, for example, by anesthetizing (by local or systemic anesthesia) an animal (including human) that serves as a source, put a needle into the sternum or iliac of the animal, and aspirating the bone marrow with a syringe. On the other hand, it is an established technique to collect cord blood at birth by putting needle directly into the umbilical cord, and aspirating the blood from the umbilical cord using syringe, and to store the blood.
- Transplantation of cells into a patient can be performed, for example, by first filling a syringe with cells to be transplanted. Herein, the cells are suspended in an artificial cerebrospinal fluid or physiological saline. Then, the damaged neural tissue is exposed by surgery, and, with a needle, directly injecting the cells into the lesion. Due to high migrating potential of cells contained in a cell fraction of the present invention, they can migrate in the neural tissues. Hence, cells can be transplanted into a region adjacent to the lesion. Moreover, injection of the cells into the cerebrospinal fluid is also expected to be efficacious. In the case of the injection of the cells into the cerebrospinal fluid, the cells can be injected into a patient by typical lumbar puncture, without surgical operation only under local anesthetization. Thus, the patient can be treated in patient's sickroom (not in an operation room), which makes the method preferable. Alternatively, intravenous injection (including any systemic transplantations such as intravenous, intraarterial, selective intraarterial administration) of the cells is also expected to be effective. Thus, transplantation can be carried out by a procedure based on typical blood transfusion, which is advantageous in that the treatment can be performed in patient's sickroom.
- Furthermore, due to their high migrating potential, cells in a cell fraction of the present invention can be used as a carrier (vector) for genes. For example, the cells are expected to be useful as a vector for gene therapy for various neurological diseases such as brain tumor.
-
FIG. 1 shows optical light micrographs of transections of dorsal column of the spinal cord, which had been prepared at 1-mm intervals. (A), normal axon; and (C), damaged demyelinated axon. Patterns of dorsal column observed at higher magnification are shown in (B) for normal axon and in (D) for demyelinated axon. Scale bars: 250 μM in (A) and (C); 10 μm in (B) and (D). -
FIG. 2 shows microphotographs demonstrating the remyelination of rat spinal cord (A), after transplantation of adult mouse bone marrow cells; and (C), after transplantation of Schwann cells. Photomicrographs demonstrating remyelinated axon observed at higher magnification are shown in (B), after transplantation of bone marrow cells; and (D), after transplantation of Schwann cells. Scale bars: 250 μm in (A) and (C); 10 μm in (B) and (D). -
FIG. 3 shows an electron micrograph of remyelinated axon after the transplantation of bone marrow into the dorsal columns. The tissue was treated with substrate X-Gal to detect transplanted bone marrow cells containing the P-galactosidase gene in the damaged tissues (the reaction product is indicated with arrow). When observed at higher magnification, basal lamina was found around the fibers (wedge-shaped mark; scale bar 1 μm). The presence of large cytoplasmic and nuclear regions and basal lamina in the transplanted cells indicates peripheral myelination. - The present invention will be described in more detail below with reference to examples based on specific experiments.
- (1) Bone Marrow Mononuclear Cells
- Mouse bone marrow cells (10 μl) were obtained from the femur of adult LacZ (a structural gene of β-galactosidase) transgenic mice (The Jackson Laboratory, Maine, USA). The collected sample was diluted in L-15 medium (2 ml) containing 3 ml Ficoll, and centrifuged at 2,000 rpm for 15 minutes. Cells were collected from the mononuclear cell fraction, and suspended in 2 ml serum-free medium (NPMM: Neural Progenitor cell Maintenance Medium). Following centrifugation (2,000 rpm, 15 min), the supernatant was removed, and precipitated cells were collected and re-suspended in NPMM.
- (2) Schwann Cells
- Primary Schwann cell cultures were established from the sciatic nerve of neonatal mouse (P1-3) according to the method of Honmou et al. (J. Neurosci., 16(10): 3199-3208, 1996). Specifically, cells were released from sciatic nerve by enzymatic and mechanical treatment. 8×105 cells per plate were plated onto 100-mm2 poly (L-lysine)-coated tissue culture plates and the cells were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 20% (vol/vol) fetal calf serum.
- (1) Preparation of Demyelinated Rat Model
- Experiments were performed on 12 week old Wistar rats. A localized demyelinated lesion was created in the dorsal columns using X-ray irradiation and ethidium bromide injection (EB-X treatment). Specifically, rats were anesthetized with ketamine (75 mg/kg) and xylazine (10 mg/kg) i.p., and a surface dose of 40 Grays of X-ray was irradiated using Softex M-150 WZ radiotherapy machine (100 kV, 1.15 mA, SSD 20 cm, dose rate 200 cGy/min) on the spinal cord caudal to the tenth thoracic spine level (T-10) through a 2×4 cm opening in a lead shield (4 mm thick). Three days after X-ray irradiation, rats were anesthetized as above, and aseptic laminectomy of the eleventh thoracic spine (T-11) was conducted. A demyelinating lesion was generated by the direct injection of ethidium bromide (EB) into the dorsal columns via a glass micropipette whose end was drawn. 0.5 μl saline containing 0.3 mg/ml EB was injected at the depths of 0.7 and 0.4 mm.
- (2) Transplantation of Stem or Progenitor Cells that can Differentiate or Transform into the Neural Lineages
- 3 days after the EB injection, 1 μl of the cell suspension (1×104 cells/μl), which was obtained in Example 1, was injected into the middle of the E3-X-induced lesion. Transplanted rats were immunosuppressed with cyclosporin A (10 mg/kg/day).
- Rats were deeply anesthetized by the administration of sodium pentobarbital (60 mg/kg, i.p.), and perfused through the heart cannula, first, with phosphate-buffer solution (PBS) and then with a fixative containing 2% glutaraldehyde and 2% paraformaldehyde in 0.14 M Sorensen's phosphate buffer, pH 7.4. Following in situ fixation for 10 minutes, the spinal cord was carefully excised, cut into 1 mm segments and kept in fresh fixative. The tissue was washed several times in Sorensen's phosphate buffer, post-fixed in 1% OsO4 for 2 hours at 25° C., dehydrated by elevating the concentration of the ethanol solution, passed through propylene oxide and embedded in EPON. Then, the tissue was cut into sections (1 μm), counterstained with 0.5% methylene blue and 0.5% azure II in 0.5% borax, and examined under light microscope (Zeiss: Axioskop FS). Ultrathin sections were counterstained with uranyl and lead salts, and examined with JEOL JEM1200EX electron microscope (JEOL, Ltd., Japan) at 60 kV.
- A 50×50 μm standardized region in the central core of the dorsal columns in the spinal cords near the site wherein the cells were initially injected was used for morphometric analysis. The numbers of remyelinated axons and cell bodies associated with the axons were counted within this region; and the density to square millimeters was calculated. Furthermore, the diameters of the axons and cell bodies, the number of cells with multi-lobular nuclei, and cells showing myelination were examined in the same standardized region. Measurements and counts were obtained from five sections per rat, and five rats (n=5) were analyzed for each experimental condition. All variances represent standard error (±SEM).
- The dorsal column in the spinal cord mostly consists of myelinated axons (
FIG. 1A , B). The proliferation of endogenous glial cells was inhibited by the irradiation of X-ray to the dorsal columns of the lumbar spinal cord. Further, by the administration of a nucleic acid chelator, ethidium bromide, glial cells such as oligodendrocytes were found damaged and local demyelination occurred. Such lesions generated according to this procedure are characterized by almost complete loss of endogenous glial cells (astrocytes and oligodendrocytes) and preservation of axons (FIG. 1C ). Examination of the lesion with a light microscope under a higher magnification revealed that congested areas consisting of demyelinated axons are appositioned closely to one another separated by areas wherein the debris of myelin exist and wherein macrophages exist (FIG. 1D ). The lesion occupied nearly the entire dorso-ventral extent of the dorsal columns 5 to 7 mm longitudinally. Almost none of the endogenous invasion of Schwann cells or astrocytes occurs till the sixth to eighth week. With the start of invasion, these glial cells begin to invade into the lesion from peripheral borders. Thus, a demyelinated and glial-free environment is present for at least 6 weeks in vivo. - Three weeks after transplantation of LacZ transgenic mouse bone marrow cells (BM) into the central region of the lesion in immunosuppressed and demyelinated rat models, extensive remyelination of the demyelinated axons was observed (
FIGS. 2A and 2B ). Remyelination was observed across the entire coronal dimension of the dorsal columns and throughout the antero-posterior extent of the lesion.FIGS. 2C and 2D show the pattern of remyelination observed after transplantation of allogeneic Schwann cells (SC) into the EB-X lesion model. It is remarkable that large nuclear and cytoplasmic regions were found around the remyelinated axons, a characteristic of peripheral myelin, by both BM and SC transplantations. - Three weeks after transplantation, β-galactosidase expressing myelin-forming cells were detected in vivo. Spinal cords were collected and fixed in 0.5% glutaraldehyde in phosphate-buffer for 1 h. Sections (100 μm) were cut with a vibratome and β-galactosidase expressing myelin-forming cells were detected by incubating the sections at 37° C. overnight with X-Gal (substrate which reacts with β-galactosidase to develop color) at a final concentration of 1 mg/ml in X-Gal developer (35 mM K3Fe(CN)6/35 mM K4Fe(CN)63H2O/2 mM MgCl2 in phosphate-buffered saline) to form blue color within the cell. Sections were then fixed for an additional 3 h in 3.6% (vol/vol) glutaraldehyde in phosphate-buffer (0.14 M), and were examined with light microscope for the presence of blue reaction product (β-galactosidase reaction product). Prior to embedding in EPON, the tissue was treated with 1% OsO4, dehydrated in a graded series of ethanol, and soaked in propylene oxide for a short period. Ultrathin sections were then examined under an electron microscope without further treatment.
- Under the electron microscope, most of the myelin-forming cells derived from donor cells retained the basal membrane (
FIG. 3 : wedge-shaped mark). Additionally, the myelin-forming cells had relatively large nucleus and cytoplasm, which suggests the formation of a peripheral nervous system-type myelin sheath. - It was confirmed that almost no endogenous remyelination by oligodendrocytes or Schwann cells Occurs for at least six weeks in the lesion model used in the present experiment. Furthermore, the donor cells that contained the reporter gene LacZ, i.e., X-Gal-positive cells, were observed to form myelin at the electron microscopic level (
FIG. 3 : arrow). - Differentiation into neurons and glial cells could be observed following the transplantation of bone marrow cells into the EB-X lesions, but not by SC transplantation. Five percent of lacZ-positive cells (transplanted bone marrow cells) in the EB-X lesions showed NSE (Neuron Specific Enolase)-immunoreactivity and 3.9% showed GFAP (Glial Fibrially Acidic Protein)-immunoreactivity indicating that some of the bone marrow cells can differentiate into neurons or glial cells, respectively, in vivo.
- Furthermore, employing antibodies, the present inventors isolated mesenchymal stem cells with the characteristic of cell markers SH2(+), SH3(+), CD29(+), CD44(+), CD14(−), CD34(−), and CD45(−) from the cell fraction obtained in Example 1 (1). Furthermore, they discovered that transplantation of the cells into the demyelinated regions of rat spinal cord results in more efficient remyelination. It was also revealed that the cells survived favorably and differentiated into neurons or neuronal cells and glia cells when transplanted into cerebral infarction model rats.
- Further, the present inventors isolated stromal cells characterized by the cell surface markers Lin (−), Sca-1(+), CD10(+), CD11D (+), CD44(+), CD45(+), CD71(+), CD90(+), CD105(+), CDW123(+), CD127(+), CD164(+), fibronectin (+), ALPH (+), and collagenase-1(+) from the cell fraction obtained in Example 1 (1). Transplantation of the cells into demyelinated regions of rat spinal cord also resulted in efficient remyelination.
- Further, the present inventors isolated cells characterized by the cell surface marker AC133(+) from the cell fraction obtained in Example 1 (1). Transplantation of the cells into demyelinated regions of rat spinal cord also resulted in efficient remyelination.
- In addition, the present inventors obtained a cell fraction containing AC133-positive cells capable of differentiating into neural cells from rat embryonic hepatic tissues by the following procedure. Specifically, first, liver tissues collected from rat fetuses were washed in L-15 solution, and then treated enzymatically in L-15 solution containing 0.01% DNaseI, 0.25% trypsin, and 0.1% collagenase at 37° C. for 30 minutes. Then, the tissue was dispersed into single cells by pipetting several times. The single-dispersed embryonic hepatic tissues were centrifuged as in Example 1 (1) (preparation of mononuclear cell fraction from femur) to isolate a mononuclear cell fraction. The obtained mononuclear cell fraction was washed, and then, AC133(+) cells were recovered from the cell fraction using anti-AC133 antibody. The isolation of AC133-positive cells can be achieved using magnetic beads or a cell sorter (FACS or the like). Transplantation of the obtained AC133-positive cells into demyelinated regions of rat spinal cord also resulted in efficient remyelination.
- As described above, the present invention provides fractions of mononuclear cells isolated and purified by collecting bone marrow-derived bone marrow cells, cord blood-derived cells, or fetal liver-derived cells. Transplantation of such mononuclear cell fractions into a demyelination model animal was confirmed to result in remyelination of the demyelinated axon.
- Cells for transplantation can be relatively easily isolated from a small quantity of bone marrow cell fluid aspirated from bone marrow, and can be prepared for transplantation in several tens of minutes after the cells are being collected. Thus, these cells can serve as useful and regenerable cellular material for autotransplantation in the treatment of demyelinating diseases.
- This invention highlights the development of the autotransplantation technique to treat demyelinating diseases in the central nervous system. Furthermore, the use of the present invention in transplantation and regeneration therapy for more general and diffuse damage in the nervous system is envisaged. In other words, this invention sheds light on autotransplantation therapy against ischemic cerebral damage, traumatic cerebral injury, cerebral degenerating diseases, and metabolic neurological diseases in the central and peripheral nervous systems.
- According to the present invention, cells in the hematopoietic system (bone marrow or cord blood) are used as donor cells. Thus, to treat neurological diseases, the cells may be transplanted into the vessels instead of directly transplanting them into neural tissues. Specifically, donor cells transplanted into a vessel can migrate to the neural tissues and thereby regenerate the neural tissues. Hence, the present invention is a breakthrough in developing a therapeutic method for relatively noninvasive transplantation.
- Furthermore, the present invention adds significantly to elucidate the mechanism underlying the differentiation of non-neural cells such as hematopoietic cells and mesenchymal, cells into neural cells. When genes determining the differentiation are identified and analyzed, use of such genes will allow efficient transformation of a sufficient quantity of non-neural cells such as hematopoietic cells and mesenchymal cells in a living body to neural cells. Thus, the present invention is a breakthrough in the field of “gene therapy” for inducing regeneration of neural tissues.
Claims (14)
1-16. (canceled)
17. A cell population isolated from bone marrow or cord blood comprising
mesenchymal stem cells that are SH2(+), SH3(+), SH4(+), CD29(+), CD44(+), CD14(−), CD34(−), and CD45(−),
wherein cells within said cell population differentiate into neurons or glia cells after transplantation into a patient.
18. A method for treating neurodegeneration, comprising
isolating the cell population of claim 1, wherein said isolation does not exclude hematopoietic cells from said cell population; and
injecting an effective amount of said isolated cell population into a patient in need of said treatment,
wherein said effective amount of said isolated cell population is effective at treating said patient's neurodegeneration.
19. The method for treating neurodegeneration according to claim 18 , wherein said neurodegeneration is caused by nerve demyelination.
20. The method for treating neurodegeneration according to claim 18 , wherein said cell population is injected intra-arterially.
21. The method for treating neurodegeneration according to claim 18 , wherein said cell population is injected intravenously.
22. The method for treating neurodegeneration according to claim 21 , wherein said cell population is injected into the carotid artery.
23. The method for treating neurodegeneration according to claim 18 , wherein cells within said injected cell population differentiate into neuron or glia cells at a site of neurodegeneration.
24. The method for treating neurodegeneration according to claim 18 , wherein said neurodegeneration is caused by ischemia.
25. The method for treating neurodegeneration according to claim 24 , wherein said neurodegeneration caused by ischemia is stroke.
26. The method for treating neurodegeneration according to claim 18 , wherein said neurodegeneration is caused by demyelination or trauma.
27. The method for treating neurodegeneration according to claim 26 , wherein said trauma is caused by spinal cord injury or brain injury.
28. The method for treating neurodegeneration according to claim 26 , wherein said demyelination is caused by spinal cord injury or multiple sclerosis.
29. The method for treating neurodegeneration according to claim 18 , wherein said neurodegeneration is associated with Alzheimer's disease, Parkinson's disease, Huntington's disease, or amyotrophic lateral sclerosis (ALS).
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/733,008 US20130195808A1 (en) | 2000-06-26 | 2013-01-02 | Mesenchymal stem cell and a method of use thereof |
Applications Claiming Priority (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2000-190421 | 2000-06-26 | ||
JP2000190421 | 2000-06-26 | ||
JP2001160579 | 2001-05-29 | ||
JP2001-160579 | 2001-05-29 | ||
PCT/JP2001/005456 WO2002000849A1 (en) | 2000-06-26 | 2001-06-26 | Cell fraction containing cells capable of differentiating into nervous system cells |
US10/330,963 US7098027B2 (en) | 2000-06-26 | 2002-12-23 | Method for remyelinating a demyelinized lesion due to injury in the brain or spinal cord |
US11/189,050 US20050282276A1 (en) | 2000-06-26 | 2005-07-26 | Cell fractions containing cells capable of differentiating into neural cells |
US12/076,092 US20080248004A1 (en) | 2000-06-26 | 2008-03-13 | Cell fractions containing cells capable of differentiating into neural cells |
US13/733,008 US20130195808A1 (en) | 2000-06-26 | 2013-01-02 | Mesenchymal stem cell and a method of use thereof |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/076,092 Continuation US20080248004A1 (en) | 2000-06-26 | 2008-03-13 | Cell fractions containing cells capable of differentiating into neural cells |
Publications (1)
Publication Number | Publication Date |
---|---|
US20130195808A1 true US20130195808A1 (en) | 2013-08-01 |
Family
ID=26594623
Family Applications (10)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/330,963 Expired - Lifetime US7098027B2 (en) | 2000-06-26 | 2002-12-23 | Method for remyelinating a demyelinized lesion due to injury in the brain or spinal cord |
US11/189,050 Abandoned US20050282276A1 (en) | 2000-06-26 | 2005-07-26 | Cell fractions containing cells capable of differentiating into neural cells |
US12/076,092 Abandoned US20080248004A1 (en) | 2000-06-26 | 2008-03-13 | Cell fractions containing cells capable of differentiating into neural cells |
US13/040,954 Abandoned US20110158967A1 (en) | 2000-06-26 | 2011-03-04 | Mesenchymal stem cell and the method of use thereof |
US13/481,180 Expired - Fee Related US9115344B2 (en) | 2000-06-26 | 2012-05-25 | Mesenchymal stem cell and a method of use thereof |
US13/481,416 Abandoned US20120230961A1 (en) | 2000-06-26 | 2012-05-25 | Mesenchymal stem cell and the method of use thereof |
US13/481,318 Abandoned US20120237487A1 (en) | 2000-06-26 | 2012-05-25 | Mesenchymal stem cell and the method of use thereof |
US13/481,308 Abandoned US20120237946A1 (en) | 2000-06-26 | 2012-05-25 | Mesenchymal stem cell and the method of use thereof |
US13/733,008 Abandoned US20130195808A1 (en) | 2000-06-26 | 2013-01-02 | Mesenchymal stem cell and a method of use thereof |
US14/723,514 Expired - Fee Related US10640749B2 (en) | 2000-06-26 | 2015-05-28 | Mesenchymal stem cell and the method of use thereof |
Family Applications Before (8)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/330,963 Expired - Lifetime US7098027B2 (en) | 2000-06-26 | 2002-12-23 | Method for remyelinating a demyelinized lesion due to injury in the brain or spinal cord |
US11/189,050 Abandoned US20050282276A1 (en) | 2000-06-26 | 2005-07-26 | Cell fractions containing cells capable of differentiating into neural cells |
US12/076,092 Abandoned US20080248004A1 (en) | 2000-06-26 | 2008-03-13 | Cell fractions containing cells capable of differentiating into neural cells |
US13/040,954 Abandoned US20110158967A1 (en) | 2000-06-26 | 2011-03-04 | Mesenchymal stem cell and the method of use thereof |
US13/481,180 Expired - Fee Related US9115344B2 (en) | 2000-06-26 | 2012-05-25 | Mesenchymal stem cell and a method of use thereof |
US13/481,416 Abandoned US20120230961A1 (en) | 2000-06-26 | 2012-05-25 | Mesenchymal stem cell and the method of use thereof |
US13/481,318 Abandoned US20120237487A1 (en) | 2000-06-26 | 2012-05-25 | Mesenchymal stem cell and the method of use thereof |
US13/481,308 Abandoned US20120237946A1 (en) | 2000-06-26 | 2012-05-25 | Mesenchymal stem cell and the method of use thereof |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/723,514 Expired - Fee Related US10640749B2 (en) | 2000-06-26 | 2015-05-28 | Mesenchymal stem cell and the method of use thereof |
Country Status (8)
Country | Link |
---|---|
US (10) | US7098027B2 (en) |
EP (3) | EP2295539A1 (en) |
JP (2) | JP4621410B2 (en) |
KR (2) | KR100947577B1 (en) |
CN (1) | CN1449439A (en) |
AU (1) | AU2001274624A1 (en) |
CA (1) | CA2413910A1 (en) |
WO (1) | WO2002000849A1 (en) |
Families Citing this family (68)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1449439A (en) * | 2000-06-26 | 2003-10-15 | 株式会社雷诺再生医学研究所 | Cell fraction containing cells capable of differentiating into nervous system cells |
EP2322601A1 (en) * | 2000-12-06 | 2011-05-18 | Anthrogenesis Corporation | Method of collecting placental stem cells |
CA2465653C (en) * | 2001-10-30 | 2013-10-08 | Renomedix Institute Inc. | Method for inducing differentiation of mesodermal stem cells, es cells, or immortalized mesodermal stem cells into neural cells |
KR100489248B1 (en) * | 2002-02-19 | 2005-05-11 | 메디포스트(주) | Isolation and culture-expansion methods of mesenchymal stem/progenitor cells from umbilical cord blood, and differentiation method of umbilical cord blood-derived mesenchymal stem/progenitor cells into various mesenchymal tissues |
US20040203142A1 (en) * | 2003-04-14 | 2004-10-14 | Reliance Life Sciences Pvt. Ltd. | Growth of neural precursor cells using umbilical cord blood serum and a process for the preparation thereof for therapeutic purposes |
US20060210544A1 (en) | 2003-06-27 | 2006-09-21 | Renomedix Institute, Inc. | Internally administered therapeutic agents for cranial nerve diseases comprising mesenchymal cells as an active ingredient |
WO2005083061A1 (en) * | 2004-02-11 | 2005-09-09 | Aldagen, Inc. | Stem cell populations and methods of use |
WO2005113751A1 (en) * | 2004-05-14 | 2005-12-01 | Becton, Dickinson And Company | Cell culture environments for the serum-free expansion of mesenchymal stem cells |
US8017395B2 (en) | 2004-12-17 | 2011-09-13 | Lifescan, Inc. | Seeding cells on porous supports |
WO2006113731A2 (en) * | 2005-04-20 | 2006-10-26 | University Of Florida Research Foundation, Inc. | Bone marrow-derived neurogenic cells and uses thereof |
AU2006202209B2 (en) * | 2005-05-27 | 2011-04-14 | Lifescan, Inc. | Amniotic fluid derived cells |
PT1888123E (en) * | 2005-06-08 | 2013-03-13 | Janssen Biotech Inc | A cellular therapy for ocular degeneration |
US8741643B2 (en) | 2006-04-28 | 2014-06-03 | Lifescan, Inc. | Differentiation of pluripotent stem cells to definitive endoderm lineage |
CA2669304C (en) | 2006-11-30 | 2016-10-25 | Medipost Co., Ltd. | Use of a composition contaning human umbilical cord blood-derived mesenchymal stem cell for inducing differentiation and proliferation of neural precursor cells or neural stem cells to neural cells |
EP2099290A4 (en) * | 2006-12-07 | 2010-01-13 | Teva Pharma | Method of generation and expansion of tissue-progenitor cells and mature tissue cells from intact bone marrow or intact umbilical cord tissue |
KR20080068352A (en) * | 2007-01-19 | 2008-07-23 | 재단법인서울대학교산학협력재단 | Neuronal regeneration material screening method by ex vivo model |
WO2008104065A1 (en) * | 2007-02-26 | 2008-09-04 | Mount Sinai Hospital | Neural cell preparations and methods of making and using them |
US9080145B2 (en) * | 2007-07-01 | 2015-07-14 | Lifescan Corporation | Single pluripotent stem cell culture |
WO2009018453A1 (en) | 2007-07-31 | 2009-02-05 | Lifescan, Inc. | Differentiation of human embryonic stem cells |
US9700582B2 (en) | 2007-09-11 | 2017-07-11 | Sapporo Medical University | Cell growth method and pharmaceutical preparation for tissue repair and regeneration |
CA2706560C (en) * | 2007-11-27 | 2017-02-28 | Lifescan, Inc. | Differentiation of human embryonic stem cells to pancreatic cells |
JP5733986B2 (en) | 2008-02-21 | 2015-06-10 | ヤンセン バイオテツク,インコーポレーテツド | Methods, surface modified plates, and compositions for cell attachment, culture and detachment |
US8318485B2 (en) * | 2008-02-25 | 2012-11-27 | Natalie Gavrilova | Stem cell therapy for the treatment of diabetic retinopathy and diabetic optic neuropathy |
US8623648B2 (en) | 2008-04-24 | 2014-01-07 | Janssen Biotech, Inc. | Treatment of pluripotent cells |
PL2942392T3 (en) | 2008-06-30 | 2019-02-28 | Janssen Biotech, Inc | Differentiation of pluripotent stem cells |
MX2011000123A (en) * | 2008-06-30 | 2011-02-25 | Centocor Ortho Biotech Inc | Differentiation of pluripotent stem cells. |
US20100028307A1 (en) * | 2008-07-31 | 2010-02-04 | O'neil John J | Pluripotent stem cell differentiation |
MX349178B (en) | 2008-10-31 | 2017-07-17 | Centocor Ortho Biotech Inc | Differentiation of human embryonic stem cells to the pancreatic endocrine lineage. |
WO2010051223A1 (en) | 2008-10-31 | 2010-05-06 | Centocor Ortho Biotech Inc. | Differentiation of human embryonic stem cells to the pancreatic endocrine lineage |
KR20100054711A (en) | 2008-11-14 | 2010-05-25 | 메디포스트(주) | Composition comprising mesenchymal stem cells or culture solution of mesenchymal stem cells for the prevention or treatment of neural diseases |
KR101687344B1 (en) * | 2008-11-20 | 2016-12-16 | 얀센 바이오테크 인코포레이티드 | Methods and compositions for cell attachment and cultivation on planar substrates |
EP2366021B1 (en) | 2008-11-20 | 2017-08-02 | Janssen Biotech, Inc. | Pluripotent stem cell culture on micro-carriers |
SG177416A1 (en) * | 2009-07-20 | 2012-02-28 | Janssen Biotech Inc | Differentiation of human embryonic stem cells |
EP2456858B1 (en) * | 2009-07-20 | 2018-08-29 | Janssen Biotech, Inc. | Differentiation of human embryonic stem cells |
WO2011011300A2 (en) | 2009-07-20 | 2011-01-27 | Centocor Ortho Biotech Inc. | Differentiation of human embryonic stem cells |
WO2011046570A1 (en) | 2009-10-16 | 2011-04-21 | The University Of Medicine And Dentistry Of New Jersey | Method for treating chronic nerve tissue injury using a cell therapy strategy |
MX339669B (en) * | 2009-12-23 | 2016-06-02 | Janssen Biotech Inc | Differentiation of human embryonic stem cells. |
RU2610176C2 (en) | 2009-12-23 | 2017-02-08 | Янссен Байотек, Инк. | Differentiation of human embryonic stem cells |
MX358451B (en) | 2010-03-01 | 2018-08-20 | Janssen Biotech Inc | Methods for purifying cells derived from pluripotent stem cells. |
ES2728900T3 (en) | 2010-05-12 | 2019-10-29 | Janssen Biotech Inc | Differentiation of human embryonic stem cells |
WO2012030538A2 (en) | 2010-08-31 | 2012-03-08 | Janssen Biotech, Inc. | Differentiation of human embryonic stem cells |
JP6218605B2 (en) | 2010-08-31 | 2017-10-25 | ヤンセン バイオテツク,インコーポレーテツド | Differentiation of human embryonic stem cells |
CA2809305C (en) | 2010-08-31 | 2019-06-11 | Janssen Biotech, Inc. | Differentiation of pluripotent stem cells |
WO2012048275A2 (en) | 2010-10-08 | 2012-04-12 | Caridianbct, Inc. | Configurable methods and systems of growing and harvesting cells in a hollow fiber bioreactor system |
CN102175501A (en) * | 2011-01-07 | 2011-09-07 | 山东省农业科学院作物研究所 | Method for preprocessing plant sample used for microscopic observation |
AU2012355698B2 (en) | 2011-12-22 | 2018-11-29 | Janssen Biotech, Inc. | Differentiation of human embryonic stem cells into single hormonal insulin positive cells |
AU2013230020B2 (en) | 2012-03-07 | 2018-08-09 | Janssen Biotech, Inc. | Defined media for expansion and maintenance of pluripotent stem cells |
EP3450542B1 (en) | 2012-06-08 | 2021-09-01 | Janssen Biotech, Inc. | Differentiation of human embryonic stem cells into pancreatic endocrine cells |
US10370644B2 (en) | 2012-12-31 | 2019-08-06 | Janssen Biotech, Inc. | Method for making human pluripotent suspension cultures and cells derived therefrom |
SG11201505112SA (en) | 2012-12-31 | 2015-07-30 | Janssen Biotech Inc | Differentiation of human embryonic stem cells into pancreatic endocrine cells using hb9 regulators |
ES2837763T3 (en) | 2012-12-31 | 2021-07-01 | Janssen Biotech Inc | Culture of human embryonic stem cells in the air-liquid interface for differentiation into pancreatic endocrine cells |
KR20150103203A (en) | 2012-12-31 | 2015-09-09 | 얀센 바이오테크 인코포레이티드 | Suspension and clustering of human pluripotent cells for differentiation into pancreatic endocrine cells |
SG11201507829SA (en) | 2013-03-21 | 2015-12-30 | Univ Kyoto | Pluripotent stem cell for neuronal differentiation induction |
EP3068867B1 (en) | 2013-11-16 | 2018-04-18 | Terumo BCT, Inc. | Expanding cells in a bioreactor |
EP3122866B1 (en) | 2014-03-25 | 2019-11-20 | Terumo BCT, Inc. | Passive replacement of media |
DK3143127T3 (en) | 2014-05-16 | 2021-09-13 | Janssen Biotech Inc | USE OF SMALL MOLECULES TO ENHANGE MAFA EXPRESSION IN ENDOCRINE PANCREAS CELLS |
CN106715676A (en) | 2014-09-26 | 2017-05-24 | 泰尔茂比司特公司 | Scheduled feed |
WO2017004592A1 (en) | 2015-07-02 | 2017-01-05 | Terumo Bct, Inc. | Cell growth with mechanical stimuli |
JP6777840B2 (en) | 2015-12-25 | 2020-10-28 | 北海道公立大学法人 札幌医科大学 | Drugs for the treatment of cerebral infarction |
MA45479A (en) | 2016-04-14 | 2019-02-20 | Janssen Biotech Inc | DIFFERENTIATION OF PLURIPOTENT STEM CELLS IN ENDODERMAL CELLS OF MIDDLE INTESTINE |
CA3022275A1 (en) | 2016-04-28 | 2017-11-02 | Sapporo Medical University | Synapse formation agent |
EP3464565A4 (en) | 2016-05-25 | 2020-01-01 | Terumo BCT, Inc. | Cell expansion |
US11685883B2 (en) | 2016-06-07 | 2023-06-27 | Terumo Bct, Inc. | Methods and systems for coating a cell growth surface |
US11104874B2 (en) | 2016-06-07 | 2021-08-31 | Terumo Bct, Inc. | Coating a bioreactor |
US11624046B2 (en) | 2017-03-31 | 2023-04-11 | Terumo Bct, Inc. | Cell expansion |
CN117247899A (en) | 2017-03-31 | 2023-12-19 | 泰尔茂比司特公司 | cell expansion |
WO2019093481A1 (en) | 2017-11-09 | 2019-05-16 | 北海道公立大学法人札幌医科大学 | Medicinal product for tissue regeneration, and preparation method therefor |
SG11202108656UA (en) | 2019-02-07 | 2021-09-29 | Univ Sapporo Medical | Pharmaceutical composition for preventing in-stent restenosis |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5108759A (en) * | 1987-04-01 | 1992-04-28 | Ranney David F | Endothelial envelopment drug carriers |
US5733542A (en) * | 1990-11-16 | 1998-03-31 | Haynesworth; Stephen E. | Enhancing bone marrow engraftment using MSCS |
US5197985A (en) * | 1990-11-16 | 1993-03-30 | Caplan Arnold I | Method for enhancing the implantation and differentiation of marrow-derived mesenchymal cells |
US5811094A (en) * | 1990-11-16 | 1998-09-22 | Osiris Therapeutics, Inc. | Connective tissue regeneration using human mesenchymal stem cell preparations |
US5633283A (en) * | 1995-01-23 | 1997-05-27 | Eli Lilly And Company | Method for treating multiple sclerosis |
US6653134B2 (en) * | 1995-03-28 | 2003-11-25 | Cp Hahnemann University | Isolated stromal cells for use in the treatment of diseases of the central nervous system |
US6117633A (en) * | 1995-12-08 | 2000-09-12 | University Technologies International Inc. | DNA sequence encoding the tumor suppressor gene ING1 |
US7189703B2 (en) * | 1998-01-09 | 2007-03-13 | Intracell, Llc | Treatment and diagnosis of alzheimer's disease |
IL141683A0 (en) * | 1998-08-31 | 2002-03-10 | Univ New York | Stem cells bearing an fgf receptor on the cell surface |
US20020168766A1 (en) | 2000-01-11 | 2002-11-14 | Gold Joseph D. | Genetically altered human pluripotent stem cells |
GB9825948D0 (en) * | 1998-11-26 | 1999-01-20 | Kings College University Of Lo | Diagnosis of spongiform disease |
US8017112B2 (en) * | 1999-05-14 | 2011-09-13 | Henry Ford Health System | Transplantation of bone marrow stromal cells for treatment of neurodegenerative diseases |
PT1183035E (en) | 1999-05-14 | 2015-03-04 | Ford Henry Health System | Bone marrow transplantation for treatment of stroke |
US20050169896A1 (en) * | 1999-05-14 | 2005-08-04 | Henry Ford Health System | Bone marrow transplantation for treatment of stroke |
US20020193301A1 (en) | 1999-08-19 | 2002-12-19 | Stem Cell Pharmaceuticals, Inc. | TGF-alpha polypeptides, functional fragments and methods of use therefor |
US6673606B1 (en) | 2000-04-12 | 2004-01-06 | The Children's Hospital Of Philadelphia | Therapeutic uses for mesenchymal stromal cells |
CN1449439A (en) * | 2000-06-26 | 2003-10-15 | 株式会社雷诺再生医学研究所 | Cell fraction containing cells capable of differentiating into nervous system cells |
US20020132343A1 (en) | 2001-03-19 | 2002-09-19 | Clark Lum | System and method for delivering umbilical cord-derived tissue-matched stem cells for transplantation |
WO2003038074A1 (en) | 2001-10-30 | 2003-05-08 | Renomedix Institute Inc. | Method of inducing differentiation of mesoblast stem cells or es cells into nerve system cells |
CA2465653C (en) * | 2001-10-30 | 2013-10-08 | Renomedix Institute Inc. | Method for inducing differentiation of mesodermal stem cells, es cells, or immortalized mesodermal stem cells into neural cells |
US20030161818A1 (en) | 2002-02-25 | 2003-08-28 | Kansas State University Research Foundation | Cultures, products and methods using stem cells |
EP1658853A4 (en) | 2003-06-27 | 2009-07-08 | Renomedix Inst Inc | Remedy for internal administration against cranial nerve diseases containing mesenchymal cells as the active ingredient |
US20070178591A1 (en) * | 2004-06-25 | 2007-08-02 | Renomedix Institute, Inc | Internally administered therapeutic agents for diseases in central and peripheral nervous system comprising mesenchymal cells as an active ingredient |
KR101100658B1 (en) * | 2003-06-27 | 2012-01-03 | 엔씨 메디컬 리서치 가부시키가이샤 | Therapeutic autologous-cell delivery support system, and method therefor |
-
2001
- 2001-06-26 CN CN01813933A patent/CN1449439A/en active Pending
- 2001-06-26 JP JP2002505965A patent/JP4621410B2/en not_active Expired - Lifetime
- 2001-06-26 AU AU2001274624A patent/AU2001274624A1/en not_active Abandoned
- 2001-06-26 CA CA 2413910 patent/CA2413910A1/en not_active Abandoned
- 2001-06-26 EP EP20100179989 patent/EP2295539A1/en not_active Withdrawn
- 2001-06-26 KR KR1020097024992A patent/KR100947577B1/en active IP Right Grant
- 2001-06-26 EP EP01941254A patent/EP1302534A4/en not_active Ceased
- 2001-06-26 WO PCT/JP2001/005456 patent/WO2002000849A1/en active Application Filing
- 2001-06-26 EP EP20100180002 patent/EP2292735A1/en not_active Ceased
-
2002
- 2002-12-23 US US10/330,963 patent/US7098027B2/en not_active Expired - Lifetime
- 2002-12-26 KR KR20027017743A patent/KR100947576B1/en active IP Right Grant
-
2005
- 2005-07-26 US US11/189,050 patent/US20050282276A1/en not_active Abandoned
-
2008
- 2008-03-13 US US12/076,092 patent/US20080248004A1/en not_active Abandoned
-
2010
- 2010-08-12 JP JP2010180888A patent/JP4782237B2/en not_active Expired - Lifetime
-
2011
- 2011-03-04 US US13/040,954 patent/US20110158967A1/en not_active Abandoned
-
2012
- 2012-05-25 US US13/481,180 patent/US9115344B2/en not_active Expired - Fee Related
- 2012-05-25 US US13/481,416 patent/US20120230961A1/en not_active Abandoned
- 2012-05-25 US US13/481,318 patent/US20120237487A1/en not_active Abandoned
- 2012-05-25 US US13/481,308 patent/US20120237946A1/en not_active Abandoned
-
2013
- 2013-01-02 US US13/733,008 patent/US20130195808A1/en not_active Abandoned
-
2015
- 2015-05-28 US US14/723,514 patent/US10640749B2/en not_active Expired - Fee Related
Non-Patent Citations (1)
Title |
---|
Zhao L.-R. et al. 2002. Human Bone Marrow Stem Cells Exhibit Neural Phenotypes and Ameliorate Neurological Deficits after Grafting into the Ischemic Brain of Rats. Exp Neurol 174: 11-20. * |
Also Published As
Publication number | Publication date |
---|---|
US20150337265A1 (en) | 2015-11-26 |
US20080248004A1 (en) | 2008-10-09 |
CA2413910A1 (en) | 2002-12-27 |
JP4621410B2 (en) | 2011-01-26 |
EP2295539A1 (en) | 2011-03-16 |
US20120237946A1 (en) | 2012-09-20 |
KR100947577B1 (en) | 2010-03-15 |
EP1302534A4 (en) | 2004-06-16 |
US20120237486A1 (en) | 2012-09-20 |
JP2010260873A (en) | 2010-11-18 |
WO2002000849A1 (en) | 2002-01-03 |
US20120237487A1 (en) | 2012-09-20 |
US20040121461A1 (en) | 2004-06-24 |
AU2001274624A1 (en) | 2002-01-08 |
KR20030032973A (en) | 2003-04-26 |
EP1302534A1 (en) | 2003-04-16 |
JPWO2002000849A1 (en) | 2004-03-04 |
US20110158967A1 (en) | 2011-06-30 |
US7098027B2 (en) | 2006-08-29 |
US10640749B2 (en) | 2020-05-05 |
US20120230961A1 (en) | 2012-09-13 |
JP4782237B2 (en) | 2011-09-28 |
EP2292735A1 (en) | 2011-03-09 |
CN1449439A (en) | 2003-10-15 |
US20050282276A1 (en) | 2005-12-22 |
US9115344B2 (en) | 2015-08-25 |
KR20090131682A (en) | 2009-12-29 |
KR100947576B1 (en) | 2010-03-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10640749B2 (en) | Mesenchymal stem cell and the method of use thereof | |
Sanchez‐Ramos | Neural cells derived from adult bone marrow and umbilical cord blood | |
US9795637B1 (en) | Human cord blood as a source of neural tissue repair of the brain and spinal cord | |
Zhou et al. | A comparison of the use of adipose-derived and bone marrow-derived stem cells for peripheral nerve regeneration in vitro and in vivo | |
CA2465653C (en) | Method for inducing differentiation of mesodermal stem cells, es cells, or immortalized mesodermal stem cells into neural cells | |
AU2001243464A1 (en) | Human cord blood as a source of neural tissue for repair of the brain and spinal cord | |
EP1658853A1 (en) | Remedy for internal administration against cranial nerve diseases containing mesenchymal cells as the active ingredient | |
Kyung et al. | Potential therapeutic clue of skin-derived progenitor cells following cytokine-mediated signal overexpressed in injured spinal cord | |
WO2003038074A1 (en) | Method of inducing differentiation of mesoblast stem cells or es cells into nerve system cells | |
Song et al. | The Search for Neural Progenitors in Bone Marrow and Umbilical Cord Blood | |
Montzka | An investigation into the characteristics and potential therapeutic application of human bone marrow-derived mesenchymal stromal cells in experimental spinal cord injury |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |
|
AS | Assignment |
Owner name: NC MEDICAL RESEARCH INC., JAPAN Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:HITACHI, LTD.;REEL/FRAME:035571/0317 Effective date: 20150327 |